Preventing Vincristine Sulfate Medication Errors

Lisa Schulmeister, RN, MN, CS, OCN®

**Clinical Pharmacology**

Vincristine sulfate is the salt of an alkaloid obtained from a flowering herb, the Madagascar periwinkle plant (*Catharanthus roseus*, formerly classified as *Vinca rosea* Linn, which caused it to be called a vinca alkaloid) (Greuter et al., 1999). Vincristine inhibits microtubule formation in the mitotic spindle, resulting in the arrest of dividing cells at the metaphase stage and, because of this action, sometimes is referred to as an antimicrotubule agent. Vincristine has a triphasic serum decay pattern; the initial, middle, and terminal half-lives are 5 minutes, 2.3
hours, and 85 hours, respectively. The primary route for excretion is the liver. Approximately 80% of a dose of vincristine appears in the feces, and 10% can be found in urine. Within 15–30 minutes following vincristine administration, about 90% of the bioavailable drug is distributed from the blood into the tissue, where it remains tightly bound (Facts and Comparisons, 2004; Rowinsky & Donehower, 2001).

Intended for IV use only, vincristine is supplied as a sterile, preservative-free solution at a concentration of 1 mg/ml in 1 mg and 2 mg vials that are refrigerated until use. The pH of vincristine ranges from 4–5; however, the drug should not be diluted in solutions that raise or lower the pH outside the range of 3.5–5.5. Prepared solutions must be refrigerated and protected from light. Vincristine can be given by IV bolus into the tubing of an infusing IV fluid or added to 50 ml infusion bags of 0.9% saline or 5% dextrose in water and rapidly infused (Facts and Comparisons, 2004; Gensia Sicor Pharmaceuticals, Inc., 1999; Mayne Pharma [USA Inc.], 2004).

Extravasation of vincristine results in irritation and tissue necrosis (Facts and Comparisons, 2004). Therefore, vesicant precautions are used when administering this drug. These precautions include ensuring the presence of a blood return before, during, and after vincristine administration; continuously monitoring patients for signs and symptoms of an extravasation while vincristine is being administered; avoiding the use of infusion pumps for vesicant administration; and educating patients about extravasation prevention and detection (Brown et al., 2001).

The major toxicity associated with vincristine is neurotoxicity, which may be dose limiting. Typically occurring as a symmetric peripheral neuropathy that is dose related, this toxicity usually can be reversed by discontinuing the drug. A common presenting symptom is paresthesia of the hands or feet. Further neurologic toxicity, including loss of deep tendon reflexes, severe pain, muscle weakness, foot or wrist drop, and rarely paralysis, can develop. Vincristine-induced autonomic dysfunction also may occur; symptoms include abdominal pain and constipation and, in severe cases, paralytic ileus (Gensia Sicor Pharmaceuticals, Inc., 1999).

The usual dose of vincristine for children weighing 10 kg or more is 2 mg/m² once a week. The adult dose is 1.4 mg/m², usually not to exceed 2 mg per dose. Dose reduction (usually 50%) may be required for patients with hepatic impairment (e.g., serum bilirubin > 3 mg/dl) (Gensia Sicor Pharmaceuticals, Inc., 1999; Mayne Pharma [USA Inc.], 2004).

**Overdosage**

Accidental overdoses of vincristine often have been attributed to omitted or unclear decimal points in the dose prescribed. This type of medication error results in a 10-fold overdose of the drug. For instance, in an early case report of a vincristine overdose, a decimal point was omitted from a handwritten order for a 3.2 mg dose of vincristine; as a result, a dose of 32 mg was administered. The overdose was discovered on the day following treatment when the 12-year-old patient experienced pain in her legs and bled from previous venipuncture sites. Marked abdominal distention developed, followed by confusion, stupor, seizures, and a coma. Supportive measures were ineffective, and the patient died 33 hours after the overdose of vincristine was administered (Kaufman, Kung, Koenig, & Giammona, 1976).

From 1970–2002, 18 case reports of patients who inadvertently received overdoses of vincristine were published. Vincristine overdoses resulted from decimal errors or errors in dose calculation or administration schedule. Signs and symptoms of vincristine overdose included sensory impairment and motor nerve involvement beginning within hours of the overdose. Involvement of cranial nerves III, IV, V, VI, VII, and X was reported, which caused loss of corneal reflexes, facial weakness, jaw pain, and hoarseness. Most patients developed a paralytic ileus, and two experienced atony of the bladder. All patients experienced some degree of cerebral dysfunction, including insomnia, agitation, confusion, and, occasionally, hallucinations and coma. Eleven patients had generalized seizure activity one to seven days following the overdose. Vincristine overdose also caused severe bone marrow depression and inappropriate anti-diuretic hormone (ADH) secretion. Presumably, vincristine acts on the hypothalamic nuclei to stimulate release of ADH. Fever also reportedly occurred. Although its exact mechanism is not known, fever may be related to direct hypothalamic stimulation. Patients who received large overdoses of vincristine did not survive. Causes of death included widespread hemorrhage and overwhelming infection. Two patients who received small overdoses recovered, but they had symptoms that were slower in onset and milder than those observed in patients who received 10-fold overdoses of vincristine (Bennison, 1971; Casteels-Vann Daele, Beirinckx, & Baines, 1977; Chae, Moon, & Kim, 1998; Grush & Morgan, 1979; Jochimsen, 1982; Kaufman et al., 1976; Kosmidis et al., 1991; Maeda et al., 1987; Stones, 1998; Thomas, Braat, Somers, & Goudsmit, 1982; Wakem & Bennett, 1975).

Not all vincristine overdoses are published in the literature; therefore, the extent of this type of medication error is unknown. The author is aware of two unpublished incidents of lethal vincristine overdoses that occurred in 2000 and 2002 that prompted legal action.

Vincristine has no antidote. Three of the patients in the published case reports were treated with leucovorin (two patients received 15 mg eight times daily for three days starting 48 hours after the vincristine overdose, and one patient received 12 mg four times daily for five days starting 24 hours after the vincristine overdose), based on the observation of a protective effect of leucovorin in mice that were given a lethal dose of vincristine. Despite leucovorin administration, one patient died from bone marrow aplasia and hemorrhage 68 hours following a 10-fold vincristine overdose. The two patients who also received leucovorin following a 10-fold vincristine overdose recovered, although a more rapid recovery time was not observed when they were compared retrospectively to patients who survived a vincristine overdose but did not receive leucovorin (Grush & Morgan, 1979; Thomas et al., 1982).

Because vincristine is metabolized rapidly by the liver and its metabolites are excreted primarily via the biliary system to the feces, only very small amounts of the drug appear in dialysate. Therefore, hemodialysis is not considered to be helpful following a vincristine overdose (Gensia Sicor Pharmaceuticals, Inc., 1999).

Treatment of a vincristine overdose is symptomatic and supportive. Close patient monitoring is necessary, and seizure precautions should be implemented. Because myelosuppression typically occurs, daily complete blood cell counts are
indicated, and blood product support may be required. Serum electrolytes and fluid balance are monitored closely to promptly detect inappropriate ADH secretion. The patient’s abdomen is observed for distention and auscultated for bowel sounds, and abdominal x-rays are indicated when an ileus is suspected.

Vincristine overdoses are preventable medication errors. Healthcare providers need to be familiar with chemotherapeutic agents and their usual dose range and administration schedule. Any dose containing a decimal point needs to be written clearly or, preferably, typed or electronically entered. Trailing zeros, as in 2.0 mg, need be avoided; 2 mg should be used instead to avoid confusion and potential overdose. Each page of order forms that contain multiple layers needs to be inspected to ensure that orders are clear and complete (e.g., a decimal point may not be visible because the person writing the orders did not press down hard enough while writing). Orders that are unclear about the administration schedule or do not specify the length of treatment need to be clarified; vincristine overdoses also have occurred when the drug was administered daily instead of weekly as prescribed (Jochimsen, 1982).

**Name Confusion**

The vinca alkaloids represent a group of drugs that have been called “look-alike, sound-alike” drugs (Hoffman & Prouix, 2003). The vinca alkaloids include agents with similar sounding names: vincristine, vinblastine, vindesine, and vinorelbine. When these drug names are handwritten on order sheets, especially in script, the drugs being prescribed may be unclear. Confusion over similar names and inadvertent selection of the wrong product when drugs with similar names are stocked closely together has been reported to cause “wrong drug” chemotherapy medication errors (Boyle, Schulmeister, Lajeunesse, & Anderson, 2002; Schulmeister, 1999).

Strategies to prevent wrong drug errors for look-alike, sound-alike drugs have been developed by pharmaceutical manufacturers and healthcare providers. For instance, manufacturers highlight or emphasize a certain part of a drug’s name on its label. Mayne Pharma (USA Inc.) in Paramus, NJ, uses what is termed “tall man” lettering when labeling its vials (e.g., vinCRISTINE Sulfate Injection), whereas Gensia Sincor Pharmaceuticals, Inc., in Irvine, CA, uses italics (e.g., Vincristine Sulfate Injection) to more clearly distinguish vincristine from vinblastine (see Figure 1). To reduce potential confusion among the vinca alkaloids, healthcare providers who do not use automated dispensing systems should avoid stocking look-alike, sound-alike drugs in close proximity to one another and label storage bins with high-alert warning stickers. Education also is paramount so that everyone who does not use automated dispensing systems should avoid confusion. Vincristine overdoses have been reported to cause “wrong drug” chemotherapy medication errors (Boyle, Schulmeister, Lajeunesse, & Anderson, 2002; Schulmeister, 1999).

**Incorrect Route of Administration**

**Inadvertent Intramuscular Injection**

Vincristine is given by IV only. In published anecdotal accounts, the drug has been injected inadvertently into the thighs of three children and into the gluteal muscle of a fourth. This type of medication error occurred as a result of a mix-up between a syringe containing vincristine and a syringe of L-asparaginase that each of the patients was scheduled to receive on the same day. The three children who received injections in the thigh were treated topically with cold compresses and an injection of 8.4% sodium bicarbonate to the affected areas. One of these children experienced pain after the inadvertent injection of vincristine, but none experienced any delayed adverse sequelae. For the fourth child who received the gluteal injection of vincristine, hot compresses were applied for 16 hours, beginning about six hours after the injection. Slight pain and erythema developed at the injection site but resolved completely within two weeks (Clark, Gallegos, & Bleyer, 1997; Okcay & Safak, 2003).

Because it is a vesicant, vincristine has the potential to cause tissue necrosis if inadvertently given subcutaneously or intramuscularly. Nurses giving chemotherapy should carefully read chemotherapy orders and drug labels, especially when multiple syringes are prepared for one patient, and administer the drugs per the correct route of administration.

Heat application is recommended for vincristine extravasations (Brown et al., 2001). In contrast, cold was applied (along with infiltration of the areas with sodium bicarbonate) to the injection areas of the three children who had been injected inadvertently with vincristine in their thighs (Clark et al., 1997). The authors of these case reports noted that tissue breakdown did not occur. Although sodium bicarbonate was used as a vincristine antidote, its role in managing vincristine extravasations or injections into the tissue has not been established. Hyaluronidase administered subcutaneously in a circumferential manner around the needle site has been used as an antidote for vincristine extravasations since the mid-1980s (Dorr & Alberts, 1985). Menzel and Farr (1998) postulated that hyaluronidase repairs tissue damage by promoting cell turnover, remodeling the tissue’s extracellular matrix components, and stimulating angiogenesis (i.e., the formation of capillaries).

From 2001–2004, the injectable formulation of hyaluronidase was available only through pharmacies that compounded the drug. Wyeth-Lederle (now Wyeth-Ayerst in Philadelphia, PA) discontinued manufacturing the drug in 2001. On May 5, 2004, the FDA approved Vitrase® (hyaluronidase for injection, Cardinal Health, Albuquerque, NM) as an adjuvant treatment to increase the absorption and dispersion of other injected drugs. The product is provided in vials containing 6,200 units of hyaluronidase that are being distributed as samples. FDA permission to market the product in vials containing 150 units is required.
units of hyaluronidase in 1 ml of a ready-to-use solution is pending. After permission is obtained (estimated by December 2004), commercial sale of the product will begin (American Society of Health-System Pharmacists® [ASHSP], 2004a, 2004b).

Hyaluronidase also can be obtained from pharmacies that compound the drug. However, compounded drugs are not FDA-approved products because the FDA has no control over the quality or consistency of the manufacturing process. In addition, compounding practices and the legal restrictions on these practices vary from state to state (ASHSP, 2004a). Clinicians need to screen suppliers that compound hyaluronidase injection and inquire about their quality control practices.

Recommendations for managing the inadvertent injection of vincristine cannot be made because few case reports have been published and patients have been treated in different ways. However, healthcare professionals should assess injection sites as well as pain in patients who inadvertently receive vincristine intramuscularly rather than by IV. Applying heat with warm compresses and elevating and resting the affected area also may be helpful.

**Inadvertent Intrathecal Administration**

Administration of vincristine via the spinal route (intrathecally via a lumbar puncture or intraventricularly via an Ommaya reservoir) rather than by IV as prescribed causes severe neurologic damage and often is fatal. In addition to harming patients, inadvertent intrathecal administration of vincristine has prompted legal action, including malpractice and manslaughter charges. In a review of 17 lethal incidents that occurred in the United Kingdom from 1970–1999 that resulted in physicians being charged with manslaughter, two were incidents in which vincristine was given intrathecally (Ferner, 2000).

The first reported account of inadvertent intrathecal vincristine administration was published in 1968 (Schochet, Lampert, & Earle, 1968). Since then, at least 20 deaths from inadvertent intrathecal vincristine administration are known to have occurred in the United States, Canada, the United Kingdom, Germany, Saudi Arabia, Singapore, and Korea. In the United Kingdom alone, the National Health Service recorded 14 incidents of inadvertent intrathecal vincristine administration that occurred from 1986–2001 (Woods, 2001). Lethal inadvertent intrathecal vincristine administration is documented to have occurred as recently as 2003 in the United States (Institute for Safe Medication Practices [ISMP], 2003).

The incidence of inadvertent intrathecal vincristine administration is not known. Some of these incidents, particularly lethal events, prompt publication. Sometimes these incidents are reported to organizations such as the ISMP but are not published as case reports. Inadvertent intrathecal vincristine administration also occasionally has received media attention.

In a February 2001 editorial in the *BMJ*, Donald Berwick, president and chief executive officer of the Institute for Healthcare Improvement in Boston, described his frustration in learning of repeated accounts of inadvertent intrathecal vincristine administration by writing, “‘Again, a young patient with leukemia is dying, not from his disease, but from an erroneous intrathecal injection of vincristine, intended for intravenous use. Again, the newspapers express outrage . . . the hospital apologizes again . . . and steps will be taken, again’” (Berwick, 2001, p. 247). Berwick raises the interesting question of how could this error happen—again and again?

Inadvertent intrathecal vincristine administration usually has occurred when a syringe containing vincristine intended for IV administration was confused with another syringe containing a drug to be given intrathecally (usually methotrexate or sometimes cytarabine). On other occasions, healthcare providers assumed vincristine was an additional intrathecal drug to be injected when syringes were mislabeled (Fernandez, Esau, Hamilton, Fitzsimmons, & Pritchard, 1998). Although intrathecal chemotherapy typically is administered by physicians and, in some cases, advanced practice nurses, this procedure often involves other nurses or healthcare personnel, such as medical assistants. Nurses or medical assistants may be responsible for preparing patients to receive intrathecal chemotherapy, setting up the required equipment and supplies, and assisting during the procedure. Presence during intrathecal chemotherapy administration provides nurses with an opportunity to verify that the correct drug and dose are being administered.

In published accounts, the typical course of events after inadvertent intrathecal vincristine administration was rapid sensory and motor dysfunction followed by encephalopathy, coma, and death. Early signs and symptoms included tremors, disorientation, and nausea and vomiting. Progressive deterioration ensued, and patients became unresponsive within one week. Ascending paralysis occurred in six patients. The time to death ranged from 7–83 days and averaged 10 days for the 17 patients who died (al Fawaz, 1992; Bain, Lantos, Djurovic, & West, 1991; Dettmeyer, Driever, Becker, Wiestler, & Madea, 2001; Fernandez et al., 1998; Gaidys, Dickerman, Walters, & Young, 1983; ISMP, 1998, 2000, 2003; Kwack et al., 1999; Lau, 1996; Manelis, Freundich, Ezekiel, & Doron, 1982; Meggs & Hoffman, 1998; Shepherd, Steuber, Starling, & Fernbach, 1978; Szyler, Liwcicz, Herrick, & Mason, 1980; Williams et al., 1983).

The patients who lived the longest were a three-year-old (time to death 83 days) (Alcaraz, Rey, Concha, & Medina, 2002) and a 59-year-old woman with acute lymphocytic leukemia who inadvertently received 2 mg of vincristine intrathecally (cytarabine was intended to be injected into her Ommaya reservoir and vincristine was intended to be given by IV). She became deeply comatose on day 11 and died on day 40 without regaining any neurologic function (Meggs & Hoffman, 1998).

Upon autopsy, typical findings caused by inadvertent intrathecal vincristine administration included grossly edematous and congested brain and spinal cord tissue with axonal degeneration and myelin loss of the spinal nerves (Kwack et al., 1999; Williams et al., 1983). Lau (1996) summarized this type of finding by describing it as “brain death.”

One report of a patient surviving inadvertent intrathecal vincristine administration involved a seven-year-old with acute lymphocytic leukemia who, one year after diagnosis, received maintenance chemotherapy that included IV vincristine and intrathecal methotrexate. She inadvertently received her usual vincristine dose intrathecally, and the error was detected halfway through the injection (the patient received approximately 0.5 mg vincristine). Immediate neurosurgical intervention included an exchange of cerebrospinal fluid (CSF) with Ringer’s lactate. The patient then was taken to the...
operating room in an upright position, and an intraventricular drain was inserted. After surgery, the patient was responsive and was taken to the intensive care unit where her subarachnoid space was flushed continuously with Ringer’s lactate for 24 hours. She also received 10 g of glutaminic acid IV followed by oral doses of 500 mg three times daily. Five days postoperatively, the patient experienced lower extremity pain and weakness that progressed to complete paraplegia. She also developed a neurogenic bladder that required intermittent catheterization. Seven years later, she remained in remission but did not regain motor function of her legs and continued to have a neurogenic bladder (Iqbal, Abdullah, Tuner, & Al-Sudairy, 2002). The researchers could not determine whether this patient’s survival occurred as a result of undergoing immediate CSF fluid exchange or if she survived because, unlike other patients who received a full dose of IV vincristine intrathecally, she received about half of the vincristine dose.

Another patient who inadvertently received a partial dose of vincristine intrathecally survived but experienced continued neurotoxicity, including a neurogenic bladder, 24 months following the incident (Zaragoza, Ritchey, & Walter, 1995). The only published account of survival following a full dose of vincristine inadvertently administered intrathecally was a 23-year-old patient with lymphoblastic lymphoma who underwent immediate CSF drainage; however, he developed ascending paralysis and became comatose after two days. The patient remained comatose for 10 months at which point his disease recurred but was not treated (Bleck & Jacobsen, 1991).

The three-year-old who inadvertently received intrathecal vincristine and died 83 days later also received CSF drainage and CSF fluid exchange. Her unusually prolonged time to death following inadvertent intrathecal vincristine administration was attributed to the immediate detection of the error and prompt CSF drainage and lavage (Alcaraz et al., 2002).

The rationale for immediate CSF drainage and lavage is to dilute and remove the inadvertently administered vincristine, thus limiting neurologic damage. This is the only known anecdotaly documented treatment (Al Ferayan, Russell, Al Wohaibi, Awada, & Scherman, 1999). Its success appears to be contingent on immediate detection of the error and likely is influenced by the amount of vincristine inadvertently administered intrathecally.

Because the consequences of inadvertent intrathecal vincristine administration are catastrophic, every effort to prevent this type of medication error should be used. In the United Kingdom, the Department of Health has taken a leading role in preventing accidental intrathecal vincristine administration by issuing mandates designed to promote the safe administration of all intrathecal chemotherapy (see Figure 2).

Not as much has been done in the United States to help prevent inadvertent intrathecal vincristine administration. Data from deaths resulting from inadvertent intrathecal vincristine administration have led to changes in United States Pharmacopoeial Convention, Inc. (USP), requirements for manufacturers and pharmacies that package and prepare ready-to-use doses of vincristine. Each dose of vincristine now has specific cautionary labeling. A label that states “FATAL IF GIVEN INTRATHECALLY. FOR INTRAVENOUS USE ONLY” is adhered to all syringes (see Figure 3). Each syringe then is placed in an overwrap that also contains this warning (see Figure 4) (Williams, 2002). However, despite this USP standard, another fatality occurred after vincristine was dispensed without this warning label on the syringe and outer wrapper; the drug inadvertently was administered intrathecally along with the prescribed intrathecal chemotherapy (ISMP, 2003).

In Australia, most hospitals prepare vincristine in a small-volume infusion bag of 50 ml normal saline as opposed to a syringe. Then, the drug is administered to adults over 5–10 minutes. The same approach is used for pediatric patients, but with a smaller volume and slower rate of infusion (Stefanou & Dooley, 2003). According to Stefanou and Dooley, “This is the only method of completely eradicating the risk of this drug accidentally being given intrathecally . . . since all published reports of intrathecal vincristine administration have been associated with preparation of the drug in a syringe” (p. 2044).

Womer and Bickert (2003) reported that routinely diluting vincristine and administering it as a short infusion have been debated in national pharmacy meetings and Internet mailing lists. The researchers did not advocate this approach, noting that, in pediatric patients, administering vincristine through a peripheral IV and a vincristine infusion, rather than bolus administration, greatly increases the risk of extravasation injury.

In developing an institutional policy for intrathecal chemotherapy administration, several concepts warrant inclusion. First, chemotherapy of any kind should be given only...
by appropriately trained staff. Intrathecal and IV chemotherapy should never be dispensed or delivered together. When a patient is scheduled to receive intrathecal and IV chemotherapy treatment, the treatment should be viewed as two distinct procedures that are to be performed at different points in time. At least two clinicians should independently verify intrathecal medications prior to their administration. Intrathecal chemotherapy should be given in designated locations only, and, ideally, the pharmacy staff should deliver intrathecal chemotherapy immediately before use. Prepared intrathecal chemotherapy never should be stored or placed on a counter on a patient care unit or in a patient’s room (Dyer, 2001; ISMP, 2003; Root & the British Oncology Pharmacy Association, 2001). In addition, Laws (2001) suggested that medical product manufacturers should develop syringes and equipment for epidural use that are noninterchangeable with IV products.

Creation of a specific IV vincristine administration policy may be warranted in facilities where both IV vincristine and intrathecal medications are administered. Adherence to the USP vincristine labeling standard is essential. Methods to distinguish vincristine from intrathecal medications also can be considered. Dispensing vincristine in small-volume infusion bags or diluting the dose to at least 10 ml to help differentiate it from intrathecal drugs, for which such a large volume is not given, may help to reduce the potential for inadvertent intrathecal vincristine administration.

A disturbing trend in the literature regarding inadvertent intrathecal vincristine administration is the use of “intrathecal vincristine” without the word “inadvertent.” Titles of journal articles, such as “Intrathecal Vincristine: Fatal Myeloneuropathy Despite Cerebrospinal Fluid Perfusion” (Alcaraz et al., 2002) or “Intrathecal Vincristine: Long-Term Survivor of Potentially Fatal Chemotherapeutic Error” (Iqbal et al., 2002), in some ways make it sound as if intrathecal vincristine is an accepted treatment. To avoid confusion, clinicians and authors should consistently refer to this type of medication error as “inadvertent intrathecal vincristine administration,” “accidental intrathecal vincristine administration,” or “erroneous intrathecal vincristine administration.”

**Summary**

“The system of medical care, like all other systems, is safe only if human error is recognized as inevitable and the system is designed to minimize the consequences” (Ferner, 2000, p. 1215). In many instances, human error is responsible for, or contributes to, serious medication errors. Medication errors involving the chemotherapeutic agent vincristine, which has a very short half-life and is rapidly tissue bound, can be debilitating or even fatal. Its primary toxicity is neurologic, and symptoms of neurotoxicity are amplified when overdoses of vincristine are administered inadvertently. In addition, vincristine is not a myelosuppressive agent, but when overdoses are administered inadvertently, patients are at high risk for bleeding and infection. Accidental injection of vincristine, a drug intended for IV use only, into the CSF or ventricle of the brain results in profound neurologic sequelae and usually death. Lastly, confusion of vincristine with other vinca alkaloids can result in the incorrect drug being administered.

All of these vincristine medication errors are preventable. Increased awareness of the potential severity of these errors, combined with designing systems and using practices to prevent medication errors, has the greatest potential for eradicating vincristine medication errors.

**Author Contact:** Lisa Schulmeister, RN, MN, CS, OCN®, can be reached at lisaschulmeister@hotmail.com, with copy to editor at rose_mary@earthlink.net.

### References


---

**Figure 4. Example of Vincristine Box Label, Syringe Label, and Plastic Overwrap**
ONF Continuing Education Examination

Preventing Vincristine Sulfate Medication Errors

Credit Hours: 1.4
Passing Score: 80%
Test ID#: 04-31/5-14
Test Processing Fee: $15

The Oncology Nursing Society is accredited as a provider of continuing education in nursing by the
• American Nurses Credentialing Center’s Commission on Accreditation
• California Board of Nursing, Provider #2850.

CE Test Questions

1. Vincristine sulfate exerts its antitumor effect by
   a. Stabilizing the mitotic spindles, thus preventing cell division.
   b. Preventing the synthesis of proteins essential for cell replication.
   c. Interfering with microtubule formation during metaphase.
   d. Altering the replication of DNA during the synthesis phase.

2. Once administered, vincristine sulfate is
   a. Taken up and tightly bound in the tissues.
   b. Largely excreted in the urine within two hours.
   c. Distributed through the body over the next 90 minutes.
   d. Eliminated in small amounts (20%) in the feces.

3. A patient who is receiving vincristine sulfate as a part of the cancer treatment complains of abdominal pain and constipation. What is the most likely reason for these symptoms?
   a. Lack of exercise
   b. Peripheral neuropathy
   c. Brain metastasis
   d. Autonomic dysfunction

4. What is the usual maximum adult dose of vincristine sulfate?
   a. 1 mg
   b. 1.4 mg
   c. 2 mg
   d. 2.8 mg

5. Vincristine sulfate overdoses have been attributed to
   a. Verbal orders that are not adequately verified.
   b. Administration of the drug by the wrong route.
   c. Unclear decimal points in the written order.
   d. Administering the drug dose too rapidly.

6. What would you monitor for in a person who has received an overdose of vincristine sulfate?
   a. Restlessness
   b. Dilute urine
   c. Bradycardia
   d. Difficulty swallowing

7. When developing a policy to prevent vincristine sulfate overdose, what would be most important to include?
   a. The drug must be diluted and given as a short-term infusion.
   b. The order must be rewritten daily for multiday dosing.
   c. A certain part of the drug’s name should be italicized or bolded.
   d. Trailing zeros must not be included in the written orders.

8. Vincristine sulfate may be given by what route(s) of administration?
   a. IV and intrathecal
   b. Subcutaneous and intraventricular
   c. Intraventricular only
   d. IV only

9. When administering vincristine sulfate via IV, which of the following is the most important precaution to take to decrease the risk of extravasation?
   a. Teach the patient about ways to prevent and detect an extravasation.
   b. Use an infusion pump to detect pressure changes in the blood vessel.
   c. Assess the patient for signs of extravasation only after the infusion is complete.
   d. Monitor for numbness and tingling in the patient’s hands and feet.

10. What intervention currently is recommended after inadvertent extravasation or injection of vincristine sulfate into the muscle?
    a. Subcutaneous infiltration with saline
    b. Subcutaneous infiltration with hydrocortisone
    c. Warm compresses
    d. Cold compresses

11. What strategies have been tried to prevent “wrong drug” errors when vincristine sulfate is ordered?
    a. The order must be rewritten daily for multiday dosing.
    b. Do not stock the drug close to others that look similar and have a similar-sounding name.
    c. The prepared drug should not be delivered with other drugs.
    d. Dye should be added so that the drug is a different color.

12. Inadvertent intrathecal administration of vincristine sulfate most commonly has occurred when
    a. The person preparing the vincristine confused it with another drug with a similar-sounding name.
    b. The vincristine syringe was confused with another syringe containing a drug to be given intrathecally.
    c. The intrathecal vincristine accidently was administered to a different patient with a similar-sounding name.
    d. The vincristine was prepared as an infusion instead of in a syringe for IV administration.

13. When assessing a person who was inadvertently given intrathecal vincristine sulfate, what early symptom would you expect to find?
    a. Diarrhea
    b. Decreased urine output
    c. Coma
    d. Tremors
14. Ready-to-use doses of vincristine sulfate prepared by manufacturers and pharmacies in the United States must meet what requirement?
   a. They must be placed in an overwrap containing a specific cautionary statement.
   b. They must be diluted in at least 10 ml of normal saline.
   c. They must include information about an antidote in case of intrathecal administration.
   d. Dye should be added so that drugs prepared for intrathecal administration can be differentiated easily.

15. A policy designed to decrease the risk of accidental intrathecal administration of vincristine sulfate most likely would include what measure?
   a. A certain portion of the name vincristine sulfate should be italicized or bolded on the label.
   b. Syringes containing intrathecal drugs and IV drugs should not be delivered together.
   c. The vincristine sulfate must be diluted in 50 ml of normal saline and given as a short infusion.
   d. Dye should be added so that drugs prepared for intrathecal administration can be differentiated easily.

---

Oncology Nursing Forum Answer/Enrollment Form

Preventing Vincristine Sulfate Medication Errors (Test ID #04-31/5-14)

To receive continuing education (CE) credit for this issue, simply
1. Read the article.
2. Oncology Nursing Society members may take the test and get results immediately on the ONS Web site. Simply log on to www.ons.org and click on Oncology Nursing Forum under the Publications heading. Use your ONS membership number to access the site, select the issue you wish to use, scroll down to find the CE test, and follow the instructions. After successfully completing the test, pay with a credit card.
3. To enroll via the mail, record your answers on the form below and complete the program evaluation (you may make copies of the form). Mail the completed answer/enrollment form along with a check or money order for $15 per test payable to the Oncology Nursing Society. Payment must be included for your examination to be processed.
4. The deadline for submitting the answer/enrollment form is two years from the date of this issue.
5. Contact hours will be awarded to RNs who successfully complete the program. Successful completion is defined as an 80% correct score on the examination and a completed evaluation program. Verification of your CE credit will be sent to you. Certificates will be mailed within six weeks following receipt of your answer/enrollment form. For more information, call 866-257-4667, ext. 6296.

Instructions: Mark your answers clearly by placing an “x” in the box next to the correct answer. This is a standard form; use only the number of spaces required for the test you are taking.

1. a 2. a 3. a 4. a 5. a 6. a 7. a 8. a 9. a 10. a
   b b b b b b b b b b b b b b b b b b b b b b
   c c c c c c c c c c c c c c c c c c c c c c
   d d d d d d d d d d d d d d d d d d d d d d

11. b 12. a 13. a 14. a 15. a 16. a 17. a 18. a 19. a 20. a
   b b b b b b b b b b b b b b b b b b b b b b
   c c c c c c c c c c c c c c c c c c c c c c
   d d d d d d d d d d d d d d d d d d d d d d

Name ___________________________ Telephone # ___________________________
Address _________________________ Social Security # _______________________
City _____________________________ State _______________ Zip _______________

State(s) of licensure/license no(s). ________________________________

Program Evaluation

1. How relevant were the objectives to the CE activity’s goal?
   Not at all Low Medium High
   □ □ □ □

2. How well did you meet the CE activity’s objectives (see page E90)?
   □ □ □ □
   Objective #1
   □ □ □ □
   Objective #2
   □ □ □ □
   Objective #3

3. To what degree were the teaching/learning resources helpful?
   □ □ □ □

4. Based on your previous knowledge and experience, do you think that the level of the information presented in the CE activity was Too basic Appropriate Too complex
   □ □ □ □

5. How long did it take you to complete the CE activity? __________ minutes

☐ My check or money order payable to the Oncology Nursing Society is enclosed. U.S. currency only. (Do not send cash.)

After completing this form, mail it to: Oncology Nursing Society, P.O. Box 3510, Pittsburgh, PA 15230-3510.

For more information or information on the status of CE certificates, call 866-257-4667, ext. 6296.

---

ONCOLOGY NURSING FORUM – VOL 31, NO 5, 2004 
E98